Ispecimen vs Quantum-si
Quantum-si is the larger business, with $2.4m of revenue in fiscal 2025 against $1.9m for Ispecimen (1.3 times as much). Quantum-si grew faster (-20.3% against -79.2%). Ispecimen kept more of each dollar of sales as profit: a net margin of -543.7% against -4160.1%.
| Latest fiscal year | IspecimenISPC, 2025 | Quantum-siQSI, 2025 |
|---|---|---|
| Revenue | $1.9m | $2.4m |
| Revenue growth | -79.2% | -20.3% |
| Net income | −$10.5m | −$101m |
| Operating margin | -465.4% | — |
| Net margin | -543.7% | -4160.1% |
| Return on equity | — | -46.5% |
| Free cash flow | −$4.2m | −$97.2m |
| Cash | $6.9m | $21.6m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 138 |
| Market value | $1.3m | $281m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 30 sales |